Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3808-3815

  Wnorowska, Urszula ^a   Niemirowicz, Katarzyna ^a   Myint, Melissa ^b   Diamond, Scott L ^b   Wróblewska, Marta ^c   Savage, Paul B ^d   Janmey, Paul A ^e   Bucki, Robert ^a,e,f  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b 1150 Vagelos Laboratories   (United States)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d Brigham Young University   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f JAN KOCHANOWSKI UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGE DNA; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CSA 13; CSA 131; CSA 90; F ACTIN; POLYPEPTIDE ANTIBIOTIC AGENT; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; CERAGENIN CSA-13; CSA-90; LIPID; PREGNANE DERIVATIVE; PROPYLAMINE; STEROID;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BIOFILM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PSEUDOMONAS AERUGINOSA; SPUTUM; ATOMIC FORCE MICROSCOPY; BIOLOGICAL MODEL; CYSTIC FIBROSIS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIOPHAGE PF1; BIOFILMS; CYSTIC FIBROSIS; HUMANS; LIPIDS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ATOMIC FORCE; MODELS, BIOLOGICAL; PREGNANES; PROPYLAMINES; PSEUDOMONAS AERUGINOSA; STEROIDS;

EID: 84935862600     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00421-15     Document Type: Article

References (33)

1. Fothergill JL, Walshaw MJ, Winstanley C. 2012. Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur Respir J 40:227-238. http://dx.doi.org/10.1183/09031936.00204411.
2. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA. 1996. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 348:639-642. http://dx.doi.org/10.1016/S0140-6736(96)05169-0.
3. Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw MJ. 2004. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59:334-336. http://dx.doi.org/10.1136/thx.2003.014258.
4. James CE, Fothergill JL, Kalwij H, Hall AJ, Cottell J, Brockhurst MA, Winstanley C. 2012. Differential infection properties of three inducible prophages from an epidemic strain of Pseudomonas aeruginosa. BMC Microbiol 12:216. http://dx.doi.org/10.1186/1471-2180-12-216.
5. McCallum SJ, Gallagher MJ, Corkill JE, Hart CA, Ledson MJ, Walshaw MJ. 2002. Spread of an epidemic Pseudomonas aeruginosa strain from a patient with cystic fibrosis (CF) to non-CF relatives. Thorax 57:559-560. http://dx.doi.org/10.1136/thorax.57.6.559.
6. Carter ME, Fothergill JL, Walshaw MJ, Rajakumar K, Kadioglu A, Winstanley C. 2010. A subtype of a Pseudomonas aeruginosa cystic fibrosis epidemic strain exhibits enhanced virulence in a murine model of acute respiratory infection. J Infect Dis 202:935-942. http://dx.doi.org/10.1086 /655781.
7. Winstanley C, Langille MG, Fothergill JL, Kukavica-Ibrulj I, Paradis-Bleau C, Sanschagrin F, Thomson NR, Winsor GL, Quail MA, Lennard N, Bignell A, Clarke L, Seeger K, Saunders D, Harris D, Parkhill J, Hancock RE, Brinkman FS, Levesque RC. 2009. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool epidemic strain of Pseudomonas aeruginosa. Genome Res 19:12-23. http://dx.doi.org/10.1101/gr.086082.
8. Kukavica-Ibrulj I, Bragonzi A, Paroni M, Winstanley C, Sanschagrin F, O'Toole GA, Levesque RC. 2008. In vivo growth of Pseudomonas aeruginosa strains PAO1 and PA14 and the hypervirulent strain LESB58 in a rat model of chronic lung infection. J Bacteriol 190:2804-2813. http://dx.doi .org/10.1128/JB.01572-07.
9. Tomas M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N. 2010. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 54:2219-2224. http://dx.doi.org/10.1128/AAC.00816-09.
10. Fothergill JL, Panagea S, Hart CA, Walshaw MJ, Pitt TL, Winstanley C. 2007. Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain. BMC Microbiol 7:45. http://dx.doi.org/10.1186 /1471-2180-7-45.
11. Lai XZ, Feng Y, Pollard J, Chin JN, Rybak MJ, Bucki R, Epand RF, Epand RM, Savage PB. 2008. Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc Chem Res 41:1233-1240. http://dx.doi.org/10 .1021/ar700270t.
12. Van Bambeke F, Mingeot-Leclercq MP, Struelens MJ, Tulkens PM. 2008. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol Sci 29:124-134. http://dx.doi.org/10.1016/j.tips.2007 .12.004.
13. Moore KS, Wehrli S, Roder H, Rogers M, Forrest JN, Jr, McCrimmon D, Zasloff M. 1993. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci U S A90:1354-1358. http://dx.doi.org/10.1073 /pnas.90.4.1354.
14. Hraiech S, Bregeon F, Brunel JM, Rolain JM, Lepidi H, Andrieu V, Raoult D, Papazian L, Roch A. 2012. Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 67:2452-2458. http://dx.doi.org/10.1093/jac /dks230.
15. Bucki R, Pastore JJ, Randhawa P, Vegners R, Weiner DJ, Janmey PA. 2004. Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin. Antimicrob Agents Chemother 48:1526-1533. http://dx.doi.org/10.1128/AAC.48.5.1526-1533.2004.
16. Zanetti M, Gennaro R, Scocchi M, Skerlavaj B. 2000. Structure and biology of cathelicidins. Adv Exp Med Biol 479:203-218. http://dx.doi.org /10.1007/0-306-46831-X-17.
17. Ding B, Taotofa U, Orsak T, Chadwell M, Savage PB. 2004. Synthesis and characterization of peptide-cationic steroid antibiotic conjugates. Org Lett 6:3433-3436. http://dx.doi.org/10.1021/ol048845t.
18. Surel U, Niemirowicz K, Marzec M, Savage P, Bucki R. 2014. Ceragenins - a new weapon to fight multidrug resistant bacterial infections. Studia Medyczne 30:207-213. http://dx.doi.org/10.5114/ms.2014.45428.
19. Epand RM, Epand RF, Savage PB. 2008. Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents. Drug News Perspect 21:307-311. http://dx.doi.org/10.1358/dnp.2008.21.6.1246829.
20. Saha S, Savage PB, Bal M. 2008. Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens. J Appl Microbiol 105:822-828. http://dx.doi.org/10.1111/j.1365 -2672.2008.03820.x.
21. Bucki R, Sostarecz AG, Byfield FJ, Savage PB, Janmey PA. 2007. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J Antimicrob Chemother 60:535-545. http://dx.doi.org/10.1093/jac/dkm218.
22. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167-193. http://dx .doi.org/10.1128/CMR.15.2.167-193.2002.
23. Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Hoiby N. 2009. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 44:547-558. http://dx.doi.org/10.1002/ppul.21011.
24. Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, Fessler MB, Malcolm KC, Vasil ML, Nick JA. 2005. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 73:3693-3701. http://dx.doi.org/10.1128/IAI.73.6 .3693-3701.2005.
25. Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM, Lory S, Greenberg EP. 2001. Gene expression in Pseudomonas aeruginosa biofilms. Nature 413:860-864. http://dx.doi.org/10.1038/35101627.
26. Webb JS, Lau M, Kjelleberg S. 2004. Bacteriophage and phenotypic variation in Pseudomonas aeruginosa biofilm development. J Bacteriol 186:8066-8073. http://dx.doi.org/10.1128/JB.186.23.8066-8073.2004.
27. Ding B, Guan Q, Walsh JP, Boswell JS, Winter TW, Winter ES, Boyd SS, Li C, Savage PB. 2002. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem 45:663-669. http://dx.doi.org/10.1021/jm0105070.
28. Deneuville E, Perrot-Minot C, Pennaforte F, Roussey M, Zahm JM, Clavel C, Puchelle E, de Bentzmann S. 1997. Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients. Am J Respir Crit Care Med 156:166-172. http://dx.doi.org/10 .1164/ajrccm.156.1.9606123.
29. Peeters E, Nelis HJ, Coenye T. 2008. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods 72:157-165. http://dx.doi.org/10.1016/j.mimet.2007.11 .010.
30. Frioni A, Conte MP, Cutone A, Longhi C, Musci G, di Patti MC, Natalizi T, Marazzato M, Lepanto MS, Puddu P, Paesano R, Valenti P, Berlutti F. 2014. Lactoferrin differently modulates the inflammatory response in epithelial models mimicking human inflammatory and infectious diseases. Biometals 27:843-856. http://dx.doi.org/10.1007/s10534 -014-9740-9.
31. Weiner DJ, Bucki R, Janmey PA. 2003. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 28:738-745. http://dx.doi.org/10.1165/rcmb .2002-0191OC.
32. Jeukens J, Boyle B, Kukavica-Ibrulj I, Ouellet MM, Aaron SD, Charette SJ, Fothergill JL, Tucker NP, Winstanley C, Levesque RC. 2014. Comparative genomics of isolates of a Pseudomonas aeruginosa epidemic strain associated with chronic lung infections of cystic fibrosis patients. PLoS One 9:e87611. http://dx.doi.org/10.1371/journal.pone.0087611.
33. Rice SA, Tan CH, Mikkelsen PJ, Kung V, Woo J, Tay M, Hauser A, McDougald D, Webb JS, Kjelleberg S. 2009. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J 3:271-282. http://dx.doi.org/10.1038/ismej.2008.109.